BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

March 25, 2024

https://www.globenewswire.com/news-release/2024/03/25/2851479/0/en/BeyondSpring-Announces-First-Patient-Dosed-with-Pembrolizumab-Plinabulin-Plus-Etoposide-Platinum-in-a-Phase-2-Investigator-initiated-Study-of-First-Line-Extensive-Stage-Small-Cell-.html

FLORHAM PARK, N.J., March 25, 2024 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ:BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that the first patient has been dosed in a Phase 2 investigator-initiated trial (IIT) with Pembrolizumab, Plinabulin, BeyondSpring’s lead asset, plus Etoposide/Platinum (EP) for first-line (1L) Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) [NCT05745350].

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.